Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC2027 in advanced solid malignancies
NCT07368478Phase 1Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BC2027 in malignant solid tumor, sponsored by BioCity Biopharma. Primary endpoints: Dose Limiting Toxicities at 21 days, Safety and Tolerability at 2 years and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
BC2027
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT07368478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368478.